100 Chapter 7 Table 2. The frequency of STAS and type of prognostic unfavorable factor(s) which were associated with STAS are shown for the published studies. Study / year % STAS Vascular invasion High grade histology Pleural invasion Stage Mutations DFS OS Onozato et al. 2013115 22.2% NS No low nuclear grade* NS NS KRAS mutation* Absence of EGFR mutation* NS * Kadota et al. 2015117 38% LVSI* VSI* Micropapillary and solid pattern* NS Higher stage* NR NR * (in limited resection group) Warth et al. 2015118 51.6 NR High Ki67 NS NR Nodal metastasis* distant metastasis* Absence of EGFR mutation* BRAF mutation* KRAS mutation NS * * Morimoto et al. 2016134 [18] 7%** LVSI* VSI* NR NS NS NR NR * Shiono and Yanagawa. 2016144 [16] 14.8% LVSI* NR * Higher stage* Absence of EGFR mutation* * * Dai et al. 2017143 30.3% NR High grade* NR NR NR * (in < 3cm tumors) * (in < 3cm tumors) Lu et al. 2017133 29.7% LVSI* Vascular invasion* High nuclear grade* High Ki67* NR Higher stage* NR $ NS Uruga et al. 2017142 47.6% LVSI* VSI* Solid* * NR NR $ (in high STAS) $ (in high STAS) Masai et al 2017141 15% LVSI* High grade* * NR NR NR NR LVSI = lymphovascular space invasion; VSI = vascular space invasion; * = statistically significant in univariate analysis, but not in multivariate analysis (p <0.05); $ = statistically significant in multivariate analysis (p<0.05); NS = statistically not significant; NR = not reported; DFS = disease free survival; OS = overall survival ** estimated in 67 micropapillary adenocarcinoma of 444 adenocarcinomas
RkJQdWJsaXNoZXIy MTk4NDMw